SCHEMBL5570240

SCHEMBL5570240

CCc1cc(CCCc2ccc(C(=O)O)c(C(=O)O)c2)ccc1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT8 Q9H7Z6 2/20 0.60
PPARA Q07869 2/20 0.56
BACE1 P56817 1/20 0.55
LCK P06239 2/20 0.52
EGFR P00533 1/20 0.52
KLKB1 P03952 1/20 0.47
CTSB P07858 1/20 0.47
MMP9 P14780 1/20 0.47
DNMT1 P26358 1/20 0.47
DNMT3B Q9UBC3 1/20 0.47
DNMT3L Q9UJW3 1/20 0.47
DNMT3A Q9Y6K1 1/20 0.47
PPARG P37231 1/20 0.46
MCL1 Q07820 1/20 0.46
HNF4A P41235 1/20 0.43
HSP90AA1 P07900 1/20 0.42
HSP90AB1 P08238 1/20 0.42
HSD17B1 P14061 1/20 0.42
RARB P10826 3/20 0.42
RARA P10276 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5595846 0.85 BACE1 (0.72) KAT8BACE1HSP90AA1HSP90AB1HSD17B1
SCHEMBL254346 0.83 KAT8 (0.54) KAT8PPARALCKEGFRKLKB1
SCHEMBL5569783 0.83 KAT8 (0.57) KAT8PPARALCKEGFRKLKB1
SCHEMBL6386713 0.81 KAT8 (0.49) KAT8PPARALCKPPARG
SCHEMBL5569389 0.81 BACE1 (0.51) KAT8PPARABACE1LCKEGFR
SCHEMBL1356365 0.80 KAT8 (0.66) KAT8PPARAPPARGRARBRARA
SCHEMBL11328457 0.80 BACE1 (0.70) KAT8PPARABACE1HSP90AA1HSP90AB1
SCHEMBL3033028 0.79 KAT8 (0.73) KAT8PPARAPPARGRARBRARA
SCHEMBL1023618 0.79 BACE1 (0.68) KAT8PPARABACE1HSP90AA1HSP90AB1
SCHEMBL2687820 0.78 KAT8 (0.62) KAT8PPARALCKEGFRKLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7312249-B2 Vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-12-25 US disclosed
EP-1537065-B1 ANALOGUES OF VITAMIN D GALDERMA RES & DEV (FR) 2006-11-02 EP disclosed
US-20050182144-A1 Novel vitamin D analogues GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182144-A1 Novel vitamin D analogues CYP24A1, CYP2R1, VDR KAT8 4452/4885PPARA 134/4885BACE1 1060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.